Boston, USA-based Verastem Oncology (Nasdaq: VSTM) today announced the appointment of Matthew Ros as chief operating officer (COO).
In his role, Mr Ros will report to Dan Paterson, president and chief executive, and will serve on the company’s executive leadership team.
“We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and the transition into a commercial-stage company, while we continue to advance our clinical programs,” said Dan Paterson, adding: “Matt is an accomplished biopharmaceutical executive with extensive experience driving business transformation. His expertise will drive invaluable operational excellence as we prepare to launch a potential first-in-class treatment combination for patients with low-grade serous ovarian cancer, a rare cancer with no approved treatments specifically for this disease, and simultaneously progress programs and partnerships to address cancers driven by the RAS/MAPK-pathway that often lack treatment options.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze